[PRNewswire] JOYSBIO HAS DEVELOPED NEW MONKEYPOX RAPID TESTS

보도자료 원문 2022. 8. 17. 15:35
자동요약 기사 제목과 주요 문장을 기반으로 자동요약한 결과입니다.
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.

"At JOYSBIO," Zhang said. "We're committed to keeping up with all infectious threats to humanity. We will continue to improve our existing tests and develop new ones as needed. The sooner one knows that they're ill, the sooner they can take proactive steps to prevent spread and take care of oneself."

이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.

글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

-- JOYSBIO, one of the world's leading manufacturers of rapid test kits, has developed two new Monkeypox tests that deliver results in 15 minutes

(TIANJIN, China, Aug. 17, 2022 PRNewswire=연합뉴스) JOYSBIO, one of the world's leading manufacturers of lateral flow rapid test kits, is proud to announce the development of two Monkeypox tests, both of which deliver results in 15 minutes or less. JOYSBIO recently launched a Monkeypox Antigen Rapid test and a Monkeypox IgM/IgG Antibody Rapid test, both are CE-IVD marked. The antigen test tests specimens from human serum, plasma, whole blood, throat swab, saliva, or lesion exudate to determine if there are monkeypox virus antigens. The IgM/IgG Antibody test uses a few drops of blood to find the antibodies that a person's body created after the monkeypox infection. Both tests are currently in clinical evaluation in Europe and showed reliable results with infected patients. More information is available at https://en.joysbio.com/monkeypox-rapid-test-kit/.

"On the heels of COVID-19, another global health concern, monkeypox," said Rick Zhang, Business Development Director for JOYSBIO. "Fortunately, we have treatments for monkeypox that can reduce the painful lesions and likelihood of death. We also have a vaccine for this disease since it's been around for a very long time. Still, before patients can be treated, they need to be properly diagnosed. Monkeypox looks like many other pox diseases. Our tests will be a great tool for healthcare professionals, especially when having limited access to PCR tests."

Monkeypox has had a historical fatality rate of 0.1% to 11% in the general population, but it is much more of a concern among children where the fatality rate can skyrocket. Knowing what one has a disease is always the first step to surviving it. With the JOYSBIO Monkeypox antigen and antibody rapid tests, getting those answers will be much faster and allow healthcare workers to protect themselves and the public better.

"At JOYSBIO," Zhang said. "We're committed to keeping up with all infectious threats to humanity. We will continue to improve our existing tests and develop new ones as needed. The sooner one knows that they're ill, the sooner they can take proactive steps to prevent spread and take care of oneself."

About JOYSBIO

JOYSBIO (Tianjin) Biotechnology Co., Ltd. is an R&D-focused Chinese biotechnology company that develops, manufactures, and supplies high-quality medical in-vitro diagnostic (IVD) rapid test kits as well as revolutionary customized reagent kits to all parts of the world. JOYSBIO was founded by a team of professionals with many years of combined technical, marketing/sales, operational, and manufacturing expertise in this industry. JOYSBIO is a world-leading lateral flow test kit developer and manufacturer that supplied more than 200 million units of SARS-COV-2 rapid test kits during the COVID-19 outbreak.

If you would like more information about this topic, please contact Rick Zhang at +86-130-7204-9899 or email at bd@joysbio.com.

Source: JOYSBIO (Tianjin) Biotechnology Co., Ltd.

[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.

(끝)

출처 : PRNewswire 보도자료

Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.

이 기사에 대해 어떻게 생각하시나요?